# Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients

> **NCT05456243** · PHASE1 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 12 (estimated)

## Conditions studied

- Kidney Transplant

## Interventions

- **BIOLOGICAL:** Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
- **BIOLOGICAL:** High dose adipose tissue derived mesenchymal stromal cells (A-MSC)

## Key facts

- **NCT ID:** NCT05456243
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-30
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05456243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05456243, "Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05456243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*